Abstract | OBJECTIVE: PATIENTS AND METHODS: After a 1-week, placebo lead-in phase, 232 treatment-seeking women with regular menstrual cycles were randomly assigned to bupropion SR 150 mg/daily (116) or placebo (116) for 12 weeks under double-blind conditions. Efficacy was assessed with the Brief Index of Sexual Functioning for Women (BISF-W), the Personal Distress Scale (PDS), the global efficacy question (GEQ; 'Did the treatment you received during the 12-week improve meaningful your sexual desire?') and overall patient satisfaction question ('Are you satisfied with the efficacy of your treatment?'). RESULTS: The mean (sd) composite score on the BISF-W, increased from 15.8 (2.6) and 15.5 (2.2) at baseline to 33.9 (4.2) and 16.9 (2.6) in the bupropion and placebo groups, respectively (P= 0.001). The odds ratio (95% confidence interval) for response in the bupropion group relative to placebo was 3.2 (2.1-6.3). The thoughts/desire score more than doubled in patients treated with bupropion (P= 0.001). At the 12-week evaluation the reduction in the PDS scale was 29.4% in bupropion and 4.7% in the placebo group (P= 0.01). In response to the GEQ, of patients in the bupropion and placebo groups, 65.3%, and 4.3%, respectively, responded 'Definitely yes' (P= 0.001). Of patients in the bupropion and placebo groups, 71.8%, and 3.7%, respectively, were definitely satisfied with the efficacy of their treatment, (P= 0.001). After 12 weeks of treatment, 82 women (78.1%) in the bupropion and five (4.9%) in the placebo group were willing to continue therapy (P= 0.001). CONCLUSIONS: The results from this study indicate that bupropion SR is an effective and well-tolerated treatment for HSDD in ovulating women. Further controlled trials are warranted.
|
Authors | Mohammad Reza Safarinejad, Seyyed Yousof Hosseini, Majid Ali Asgari, Farid Dadkhah, Arsia Taghva |
Journal | BJU international
(BJU Int)
Vol. 106
Issue 6
Pg. 832-9
(Sep 2010)
ISSN: 1464-410X [Electronic] England |
PMID | 20151970
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Dopamine Uptake Inhibitors
- Bupropion
|
Topics |
- Adult
- Bupropion
(adverse effects, therapeutic use)
- Dopamine Uptake Inhibitors
(adverse effects, therapeutic use)
- Epidemiologic Methods
- Female
- Humans
- Libido
(drug effects)
- Menstrual Cycle
- Ovulation
- Patient Satisfaction
- Sexual Dysfunctions, Psychological
(drug therapy)
- Treatment Outcome
- Young Adult
|